Abstract
Pharmacological strategies for Parkinson’s disease aim to alleviate disabling motor symptoms by dopamine supplementation using a prodrug (levodopa) or receptor agonist (e.g. ropinirole). However, oral delivery results in non-physiological dopaminergic stimulation at striatal nuclei, and off-target effects.
To circumvent these issues, we present proof of concept of a novel, ultrasound (US)-mediated system capable of releasing ropinirole from packaged liposomes (ropinisomes) in targeted areas.